Advanced Filters
noise

Hialeah Gardens, Florida Clinical Trials

A listing of Hialeah Gardens, Florida clinical trials actively recruiting patient volunteers.

Found 830 clinical trials
D Deena Cilien, DPT

A Novel Repetitive Synchronized Associative Stimulation Neuromodulation Approach for Spinal Cord Injury Patients

The purpose of this research is to explore the effect of magnetic stimulation to activate the brain, electrical spinal cord stimulation to activate spinal cord, and electrical muscle stimulation used to activate upper limb (arms), lower limb (legs) and trunk (stomach) muscles in people with spinal cord injury (SCI) and …

18 - 70 years of age All Phase N/A

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

18 years of age Male Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: Screening period: 2 to 4 weeks. Treatment period: 24 weeks. Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). …

6 - 17 years of age All Phase 3
M MICHELE JEAN-GILLES, PhD

Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes

The goal of this clinical trial is to test a culturally tailored engagement and retention intervention for Haitian Immigrants Living With HIV (HILWH). The main questions it aims to answer are: Does this intervention result in measurable engagement and retention in care? Does this intervention result in measurable viral suppression …

18 years of age All Phase N/A

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.

6 - 17 years of age All Phase 4
G Guillermo Mederos

Gut-Brain Neural Coupling in Spinal Cord Injury

The purpose of this research is to determine the effects of food on brain and stomach activity in persons with and without spinal cord injury (SCI).

18 - 70 years of age All Phase N/A
A Arcutis Biotherapeutics, Inc.

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.

2 - 12 years of age All Phase 1
A Amanda Virgets, MS

Power Training Progression Methods

This study will investigate the impact of two unique progression models for power training in a sample of healthy older adults. The objective is to identify the most practical methodology for implementing power training, which is considered a critical marker of functional capacity in older populations.

50 - 90 years of age All Phase N/A
A Amanda Virgets, MS

Low Versus High Load Training and Parkinson's Disease

This study will compare the effects of high-load resistance training to low-load resistance training, on measures of muscle strength and power and tests of daily performance in older adults with Parkinson's disease.

50 - 85 years of age All Phase N/A
J Jayesh Sanmukhani

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of hormone receptor-positive breast cancer. Participants will: Receive either the test product (KSHN001034) or the reference product (Faslodex®) …

45 - 60 years of age Female Phase 1

Simplify language using AI